BioCryst Pharmaceuticals On Our Radar: Can ORLADEYO™ Cause Another Revival?
BCRX

Breakout Stocks   Corona Virus Stocks  This week BioCryst Pharmaceuticals, Inc. ($BCRX) announced FDA approval of ORLADEYO™ (berotralstat), the first oral and once-daily therapy to prevent seizures in hereditary angioedema patients. To top it all off, the company subsequently announced a $325 million financing together with Royalty Pharma and Athyrium Capital Management. ORLADEYO™ ORLADEYO™ offers patients with…

The Covid-19 Detection Gate of Predictive AI: Security Should Not Come at the Expense of Our Privacy
PAI:CA

This year the coronavirus is the number one topic of conversation worldwide. While an infinite number of companies have run into problems, other entrepreneurs saw their chance and immediately responded to the problems surrounding the pandemic. One of those innovative companies is Predictiv AI, Inc. (TSX VENTURE: PAI) (OTC: INOTF) (FRANKFURT: 71TA) that introduced the…

Vaxart Offers Advantages With VXA-CoV2-1: An Approved Vaccine Is Just The Beginning
VXRT

Vaxart, Inc. ($VXRT) continues to attract attention thanks to its oral covid-19 vaccine candidate called VXA-CoV2-1, which lately is paying off in green numbers again. As an FDA-approved corona vaccine approaches, attention is increasingly shifting to the logistics issue, where the transportation of non-oral vaccine candidates faces serious difficulties. An approved vaccine is just the…

XpresSpa is Expanding: Why Security at Airports is Essential in the Coming Years
XSPA

XpresSpa Group Inc. ($XSPA) today announced a new XpresCheck™ at Phoenix Airport. This is a promising and well-received coronavirus testing facility that allows passengers and workers at various airports to have a corona test carried out quickly and efficiently. Phoenix will be ​​the 4th battlefield to operate The company has continued to expand since transforming…

Biocept Important In The Fight Against Breast Cancer: Is 2021 An Essential Year?
BIOC

Biocept Inc. ($BIOC) recently released its third-quarter results, which showed that revenue had quadrupled year-over-year (revenues of $6.6 million). This was explained by analysts on the basis of a strategically strong move by offering a molecular diagnostics to test the coronavirus (RT-PCR test). Offering COVID-19 testing services has been the right choice and is expected…